ABEONA THERAPEUTICS INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ABEO in the last 7 days.
Abeona Therapeutics (ABEO) reported Q2 revenue of $11.4M, up 31% from Q1, driven by its gene therapy ZEVASKYN. The company treated 12 patients, with 5 in Q2 and 3 more in Q3 to date. It secured a new technology add-on payment from CMS. However, net loss widened to $20.2M, and cancellations due to manufacturing issues were noted.
Abeona Therapeutics reported treating 12 patients since launch, with 5 in Q2 2026, but revenue recognized for only 4 due to manufacturing variability. It activated 7 qualified treatment centers by year-end goal. Q2 gross margin was 63%, with normalized 85% to 90% expected. Cash was $146.8M at June 30, 2026. CMS NTAP starts Oct 1, 2026.
Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.
Recent ABEO coverage spans earnings, insider activity and regulation.
In the last 30 days, ABEO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($88K). The most active reporter was Alvino Mark with 1 filing.
Earnings beat on revenue growth but widening loss; cash balance remains strong.
Near-term valuation risk hinges on whether manufacturing yield and identity-test specs can support consistent revenue recognition, not just patient treatment counts.
The quarter shows a sharp earnings swing driven by the absence of a prior-year priority review voucher gain, alongside higher operating revenue and limited ZEVASKYN treatment volume.
Execution risk around ZEVASKYN commercial scale-up is the immediate driver, with revenue recognition impacted by a batch below the sheet threshold.
Near-term sentiment should improve on NTAP status and expanding QTC network, but cash burn and manufacturing-yield revenue recognition remain key risks.
alphai scores every news story that mentions ABEO with an AI model for sentiment and relevance, and aggregates insider trades from ABEONA THERAPEUTICS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Abeona Therapeutics (ABEO) reported Q2 revenue of $11.4M, up 31% from Q1, driven by its gene therapy ZEVASKYN. The company treated 12 patients, with 5 in Q2 and 3 more in Q3 to date. It secured a new technology add-on payment from CMS. However, net loss widened to $20.2M, and cancellations due to manufacturing issues were noted.
3 min readAbeona Therapeutics reported treating 12 patients since launch, with 5 in Q2 2026, but revenue recognized for only 4 due to manufacturing variability. It activated 7 qualified treatment centers by year-end goal. Q2 gross margin was 63%, with normalized 85% to 90% expected. Cash was $146.8M at June 30, 2026. CMS NTAP starts Oct 1, 2026.
6 min readAbeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.
4 min readAbeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.
4 min readABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau
4 min readAbeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.
4 min readVazzano Joseph Walter (Chief Financial Officer) sold 24,880 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.17M total) on 2026-07-09.
2 min readSeshadri Vishwas (Chief Executive Officer) sold 67,971 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.47M total) on 2026-07-09.
2 min readSilverstein Christine Berni sold 18,160 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.71 ($0.10M total) on 2026-06-15.
1 min readABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000318306 0000318306 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
3 min read
